Retrospective Analysis of the Effectiveness of Somatostatin Analogs in the Treatment of Metastatic Pheochromocytoma/Paraganglioma. A Clinical Case on the efficacy of long-acting release octreotide
Authors:
- Y. A. ZhulikovYZY. A. Zhulikov
- E. I. KovalenkoEKE. I. Kovalenko
- K. N. GalanovaKGK. N. Galanova
- A. N. TyatyushkinaATA. N. Tyatyushkina
- E. V. EvdokimovaEEE. V. Evdokimova
- A. A. MarkovichAMA. A. Markovich
- V. Yu. BokhyanVBV. Yu. Bokhyan
- M. M. GabravaMGM. M. Gabrava
- O. A. MartynovaOMO. A. Martynova
- V. V. DelektorskayaVDV. V. Delektorskaya
- V. A. GorbunovaVGV. A. Gorbunova
- E. V. ArtamonovaEAE. V. Artamonova
- 3 July 2025
- journal article
- Published by Alfmed LLC in Medical alphabet
- No. 11,p. 49-54
Abstract
Introduction. Pheochromocytoma (PC) and paraganglioma (PG) are neuroendocrine neoplasms and are characterized by a high frequency of somatostatin receptor (SSTR) expression. The efficacy of somatostatin analogues in PC/PG remains poorly studied, despite the lack of evidence base, these drugs are included in the international NCCN recommendations. The aim of this study was to investigate the effectiveness of somatostatin analogues in the treatment of PC/PG.Materials and methods. This retrospective single-center study included patients older than 18 years with positive expression of SSTR 2A и/или SSTR 5 or with accumulation of 68Ga-DOTATATE who received somatostatin analogs (octreotide-depo or lanreotide) at the first line of treatment for metastatic PC/PG from April 2020 to September 2023.Results. The study included 8 patients, 6 male (75 %) and 2 female (25 %). All patients had positive SSTR 2A expression and accumulation on 68Ga-DOTATATE PET. Half patients (N=4, 50 %) had pheochromocytoma and half (N=4, 50 %) paraganglioma. SDHB mutation was detected in 1 (12.5 %) patient. Four patients (50 %) had disease progression on follow-up before starting therapy with somatostatin analogues. No objective response was achieved (0 %). However, all patients had disease control ≥ 6 months. Two (33.3 %) of 6 had a ≥ 50 % decrease in metanephrine/ normetanephrine secretion. Median PFS was 21.57 months. (95 % Confidence Interval 14.95–28.19).Conclusion. Based on our findings, we recommend considering somatostatin analogs as a first-line treatment option for patients with indolent disease course and low tumor burden who demonstrate progression during active surveillance. The impact of long-acting somatostatin analogs on catecholamine secretion warrants further investigation in a prospective cohort.Keywords
This publication has 26 references indexed in Scilit:
- 1151P Biochemical and radiological efficacy of systmic lanreotide therapy of patients with advanced, unresectable, non-metastatic paraganglioma/pheochromocytoma (PPGL) sporadic and hereditaryAnnals of Oncology, 2024
- European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paragangliomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomasHuman Pathology, 2019
- Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine TumoursEndocrine Pathology, 2017
- Peptide Receptor Radionuclide Treatment and (131)I‐MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomasJournal of Surgical Oncology, 2017
- Comprehensive Molecular Characterization of Pheochromocytoma and ParagangliomaCancer Cell, 2017
- Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneityNature Reviews Cancer, 2014
- SDH Mutations Establish a Hypermethylator Phenotype in ParagangliomaCancer Cell, 2013
- The role of complex II in diseaseBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2013
- Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylaseCancer Cell, 2005